{"protocolSection": {"identificationModule": {"nctId": "NCT04071626", "orgStudyIdInfo": {"id": "STUDY20190016"}, "organization": {"fullName": "University Hospitals Cleveland Medical Center", "class": "OTHER"}, "briefTitle": "Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure", "officialTitle": "The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure", "acronym": "EMMED-HF"}, "statusModule": {"statusVerifiedDate": "2023-12", "overallStatus": "TERMINATED", "whyStopped": "Lack of enrollment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-01-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-01-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-08-26", "studyFirstSubmitQcDate": "2019-08-26", "studyFirstPostDateStruct": {"date": "2019-08-28", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-10-12", "resultsFirstSubmitQcDate": "2023-12-11", "resultsFirstPostDateStruct": {"date": "2023-12-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-12-11", "lastUpdatePostDateStruct": {"date": "2023-12-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Trevor Jenkins", "investigatorTitle": "Assistant Professor of Medicine, Department of Medicine, Case Western Reserve University / UH Cleveland Medical Center", "investigatorAffiliation": "University Hospitals Cleveland Medical Center"}, "leadSponsor": {"name": "University Hospitals Cleveland Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.", "detailedDescription": "The results of recent sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy clinical trials demonstrate clinically significant reductions in cardiovascular endpoints (myocardial infarction, cardiac death, heart failure hospitalization). SGLT2 inhibition appears to exert cardiovascular protection through pleiotrophic effects involving both the myocardium and peripheral organs but the primary pathway of risk reduction of heart failure incidents has not been elucidated. SGLT2 inhibitors induce a loss of 50-100 grams of glucose through urinary excretion daily. There is a compensatory increase in ketone body production in the liver after initiation of SGLT inhibition. Ketone bodies are the most energy efficient myocardial fuel source and reduce myocardial oxidative stress when consumed as the primary energy substrate. Inducing a shift to ketone body metabolism to improves cardiac diastolic performance suggests a unifying paradigm of direct myocardial effect and peripheral metabolic flexibility through which SGLT2 inhibition mediates myocardial protection in HFpEF.\n\nSpecific Aims Aim 1: Determine if 12 weeks of SGLTi2 therapy improves peak exercise oxygen uptake compared to placebo. We will perform cardiac MRI exercise testing (CPET-ExMR) before and \\& post 12 weeks of therapy to measure cardiopulmonary fitness by metabolic cart gas exchange and left ventricular myocardial mass.\n\nAim 2: Evaluate the short term (12 weeks effect of SGLTi on metabolic flexibility in HFpEF compared to baseline function and control group. We will measure glucose and lipid metabolism response to SGLT2 inhibition. Serum samples of glucose and ketone bodies (\u03b2-hydroxybutyrate) will be assessed before \\& post 12 weeks of therapy. Serial serum samples will allow us to generate metabolomics profiles before and after treatment. This experimental design will provide insight into ketone body production, peripheral glucose flux, and circulating lipoparticles in response to SGLTi therapy."}, "conditionsModule": {"conditions": ["Heart Failure, Diastolic", "Diabetes Mellitus, Type 2"], "keywords": ["ertugliflozin", "SGLT2 inhibtion", "Cardiovascular Diseases", "Sodium-Glucose Transporter 2 Inhibitors", "Glucose Metabolism Disorders", "Physiological Effects of Drugs", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Endocrine System Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Parallel assignment, active controlled, single center experimental design.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "Single-blind study", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 9, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertugliflozin Treatment Arm", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks", "interventionNames": ["Drug: Ertugliflozin 5 mg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo tablet once a day for 12 weeks", "interventionNames": ["Drug: Placebo oral tablet"]}], "interventions": [{"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg once a day for 12 weeks", "armGroupLabels": ["Ertugliflozin Treatment Arm"]}, {"type": "DRUG", "name": "Placebo oral tablet", "description": "Placebo oral tablet once a day for 12 weeks", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange", "description": "The difference in peak oxygen uptake as measured by peak VO2 (ml/kg/min) between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Left Ventricular Mass Index (gm/m2), as Measured by Cardiac MRI", "description": "The difference in LV mass index (gm/m2) measured by cardiac MRI between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "timeFrame": "12 weeks"}, {"measure": "Serum Ketone Bodies (Betahydroxybutyrate)", "description": "The difference in serum ketone bodies (betahydroxybutyrate) levels between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18 years old but \\< 75 years old\n* No HF hospitalization within 6 months\n* Overweight or Obesity defined as BMI \\> 29 but \\< 42\n* History of insulin resistance or T2DM and on oral diabetes agents other than SGLT2i (HgbA1c \\> 5.8% and \\< 10.5%)\n* EF calculated based on a recent echo/cath/nuclear study at screening (pre-enrollment) \\> 50%\n* Stable HFpEF (HF with preserved ejection fraction) medications use of 3 months with no plans to changes or add medications for at least 12 weeks course of the study)\n\nExclusion Criteria:\n\n* Acute HFpEF hospitalization within 6 months of enrollment.\n* CKD stage 4 or 5 (eGFR \\< 30 ml/min by CKD-EPI equation).\n* Other known causes of HF including poorly controlled hypertension (SBP \\>160 mm Hg) or ischemic cardiomyopathy (etc).\n* Anemia (Hgb \\< 11.0 mg/dL for women and \\< 12.0 mg/dL for men) or severe thrombocytopenia (platelets \\< 50,000 mm3)\n* Anticipated changing of HF medication during anticipated study period.\n* HFREF (LV EF \\< 50%).\n* Acute coronary syndrome, transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months. Severe life threatening illness or live expectancy \\< 6 months.\n* Contraindications to MRI (metallic implants, severe claustrophobia) or treadmill exercise (limb amputation, severe osteoarthritis or equivalent functional mechanical limitation).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Trevor L Jenkins, MD", "affiliation": "University Hospitals Cleveland Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Hospitals Cleveland Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks"}, {"id": "FG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks"}, {"id": "BG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange", "description": "The difference in peak oxygen uptake as measured by peak VO2 (ml/kg/min) between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Peak VO2, ml/kg/min", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "1.13"}, {"groupId": "OG001", "value": "-0.1", "spread": "1.23"}]}]}]}, {"type": "SECONDARY", "title": "Left Ventricular Mass Index (gm/m2), as Measured by Cardiac MRI", "description": "The difference in LV mass index (gm/m2) measured by cardiac MRI between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "populationDescription": "Data not collected.", "reportingStatus": "POSTED", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Serum Ketone Bodies (Betahydroxybutyrate)", "description": "The difference in serum ketone bodies (betahydroxybutyrate) levels between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.045", "spread": "0.078"}, {"groupId": "OG001", "value": "-0.018", "spread": "0.028"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "12 weeks", "eventGroups": [{"id": "EG000", "title": "Ertugliflozin Treatment Arm", "description": "Ertugliflozin 5 mg tablet once a day for 12 weeks\n\nErtugliflozin 5 mg: Ertugliflozin 5 mg once a day for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 0, "otherNumAtRisk": 5}, {"id": "EG001", "title": "Placebo", "description": "Placebo tablet once a day for 12 weeks\n\nPlacebo oral tablet: Placebo oral tablet once a day for 12 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Trevor Jenkins", "organization": "University Hospitals Cleveland Medical Center", "email": "Trevor.Jenkins@UHhospitals.org", "phone": "(216)844-1229"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2021-12-03", "uploadDate": "2023-09-05T12:27", "filename": "Prot_SAP_000.pdf", "size": 966734}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-11-02", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}, {"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Heart Failure, Diastolic", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}